Clinical trials: Hypertension, Essential
Essential Hypertension
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the…
- Trial name
- NCT02944734
- Testing
- Candesartan Cilexetil 8mg, Candesartan Cilexetil 16mg, Amlodipine 5mg
- Where
- 23 sites in South Korea
- Volunteers
- 392 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.
- Trial name
- NCT00262236
- Testing
- Aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 693 people
- Sponsor
- Novartis
Hypertension
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients.
- Trial name
- NCT00338936
- Testing
- Valsartan + Hydrochlorothiazide
- Volunteers
- 362 people
- Sponsor
- Novartis
Prevention, Arterial Hypertension
Possibilities of Perceiving Information on the Primary Prevention of Cardiovascular Diseases in Persons Suffering From Essential Hypertension Through a Social Network
A randomized, prospective study conducted on the basis of a social network (Instagram platform), two-stage. At the first stage, the online school "Save Your Heart" was announced and 945 applicants were enrolled in the training.
- Trial name
- SocialCor (NCT04944472)
- Testing
- HDKQ questionnaire
- Where
- Russia
- Volunteers
- 125 people
- Sponsor
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Hypertension
LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the…
- Trial name
- NCT00496834
- Testing
- losartan potassium, Comparator: carvedilol, Comparator: losartan (+) hydrochlorothiazide (HCTZ)
- Volunteers
- 201 people
- Sponsor
- Organon and Co
Essential Hypertension
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
- Trial name
- NCT02603809
- Testing
- Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg
- Where
- 90 sites in United States, Canada and 2 more
- Volunteers
- 1,659 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Hypertension, Sexual Dysfunction
Combined Antihypertensive Therapy and Sexual Dysfunction
This randomized,active controlled study aimed to compare the effects on sexual function of treatment with combined antihypertensive drugs. The researchers hypothesize that: 1.
- Trial name
- NCT01238705
- Testing
- Felodipine add Irbesartan, Felodipine add Metoprolol
- Where
- China
- Volunteers
- 280 people
- Sponsor
- LanZhou University
Essential Hypertension
Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial tested the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive…
- Trial name
- VALUE (NCT06395194)
- Testing
- Cardiac outcomes on treatment with valsartan, Cardiac outcomes on treatment with amlodipine
- Volunteers
- 15,313 people
- Sponsor
- Oslo University Hospital
Primary Aldosteronism, Essential Hypertension
Microvascular Function in Primary Aldosteronism
Patients with primary aldosteronism, which is the most prevalent form of secondary hypertension, have an increased rate of cardiovascular events, compared to patients with essential hypertension, even with equal severity of…
- Trial name
- NCT02096939
- Testing
- Adrenal extirpation, Antihypertensive medication
- Sponsor
- Maastricht University Medical Center
Essential Hypertension
Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
This is an 8-week, randomized, double-blind Phase 3, multicentre study to determine the optimal dose of AZM and AML in combination therapy and to compare efficacy and tolerability of the combined therapy to each of the…
- Trial name
- NCT05385770
- Testing
- AZM X mg + AML Y mg, AZM X mg + AML Y' mg, AZM X' mg + AML Y mg
- Where
- South Korea
- Volunteers
- 890 people
- Sponsor
- Celltrion
Hypertension
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d.
- Trial name
- NCT00250562
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 1,171 people, healthy volunteers welcome
- Sponsor
- Novartis
Hypertension
A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension
The purpose of this study is to determine a safe and effective dose of ADX415 for the treatment of hypertension.
- Trial name
- NCT00779181
- Testing
- ADX415
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Addrenex Pharmaceuticals, Inc.
Essential Hypertension
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.
The purpose of this study was to evaluate the efficacy and the safety of a fixed-dose combination in capsule of Amlodipine 5mg/ Bisoprolol fumarate 5mg/ Perindopril arginine 5mg, and free monotherapy at the same dose in patients…
- Trial name
- NCT05288400
- Testing
- Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg, Norvasc 5mg tablet, Concor 5mg tablet
- Where
- 15 sites in Russia
- Volunteers
- 150 people
- Sponsor
- Servier
Untreated Essential Hypertension
Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension
β-blockers (BBs) with different pharmacological properties may have heterogeneous effects on sympathetic nervous activity (SNA) and central aortic pressure (CAP), which are independent cardiovascular factors for hypertension.
- Trial name
- NCT01762436
- Testing
- bisoprolol, atenolol
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Ruijin Hospital
Primary Hypertension
The Effect of Self-Titration and Predictors for Blood Pressure Control in Patients With Hypertension
This study aims to investigate the relationship among self-efficacy, anxiety, depressive symptoms, quality of life, lifestyle, heart rate variability and blood pressure control; and to examine the effects of self-titration…
- Trial name
- NCT03470974
- Testing
- Self-titration strategy
- Where
- Taiwan
- Volunteers
- 222 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Hypertension
Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension
This will be a multi-center, prospective, randomized, open-label, parallel design, two arm comparator trial. In the proposed study, the investigators will compare low-dose combination therapy of Nifedipine GITS/OROS plus…
- Trial name
- NCT00993109
- Testing
- Adalat (Nifedipine, BAYA1040), Diovan (Valsartan)
- Where
- 17 sites in China, South Korea
- Volunteers
- 360 people
- Sponsor
- Bayer
Hypertension (HTN), Heart Failure With Preserved Ejection Fraction (HFpEF
Clinical Feasibility of Cardiac Neuromodulation Therapy for Heart Failure With Preserved Ejection Fraction
This is an open-label pilot study to evaluate the feasibility of Cardiac Neuromodulation Therapy (CNT) in patients with high blood pressure and heart failure who require dual-chamber pacemaker implantation or replacement.
- Conditions
- Hypertension (HTN), Heart Failure With Preserved Ejection Fraction (HFpEF, Hypertension, Systolic
- Trial name
- NCT07598760
- Testing
- Moderato Plus device with Cardiac Neuromodulation Therapy
- Where
- 2 sites in Georgia
- Volunteers
- 20 people
- Sponsor
- BackBeat Medical Inc
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Essential Hypertension
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy.
- Trial name
- NCT01631227
- Testing
- Eprosartan, Eprosartan Mesylate
- Where
- 38 sites in Germany, Russia and 1 more
- Volunteers
- 665 people
- Sponsor
- Abbott